

# Visceral Pain - Pipeline Review, H2 2018

<https://marketpublishers.com/r/V8DFF267E49EN.html>

Date: August 2018

Pages: 113

Price: US\$ 2,000.00 (Single User License)

ID: V8DFF267E49EN

## Abstracts

Visceral Pain - Pipeline Review, H2 2018

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2018, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape.

Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pain modifiers such as tricyclic antidepressants or anticonvulsants.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Visceral Pain - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Visceral Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Visceral Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 18 and 1

respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 6 molecules, respectively.

Visceral Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Visceral Pain (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Visceral Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Visceral Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Visceral Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Visceral Pain (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Visceral Pain (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Visceral Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction
Global Markets Direct Report Coverage
Visceral Pain - Overview
Visceral Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Visceral Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Visceral Pain - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Anavex Life Sciences Corp
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Astellas Pharma Inc
Cadila Healthcare Ltd
Chromocell Corp
Echo Pharmaceuticals BV
Eisai Co Ltd
Eli Lilly and Co
Grunenthal GmbH
Idera Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
Pfizer Inc
UCB SA
Urogen Pharmaceuticals Inc
Xigen SA
Visceral Pain - Drug Profiles
ADX-71743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-1066 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit NLRP3 for Interstitial Cystitis and Uveitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ART-26.12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-8464 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress  
E-2508 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
F-16357 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
GM-0111 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
GRT-6010 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
HS-665 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ICE-3682 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
lidocaine - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
linaclotide DR2 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
LP-08 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
mesalamine - Drug Profile  
Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain  
- Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-6860 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olorinab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPA1 for Acute Pain and Chronic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize OXTR for Abdominal Pain and Chronic Visceral Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URG-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZH-853 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYKR-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Visceral Pain - Dormant Projects



Visceral Pain - Discontinued Products

Visceral Pain - Product Development Milestones

Featured News & Press Releases

May 22, 2018: Alivio Therapeutics Announces Issuance of Two U.S. Patents Broadly Covering Compositions of Matter for Inflammation-Targeting Technology Platform

Jul 13, 2017: PureTech Health Presents Data Supporting Treatment Approach for Interstitial Cystitis/Bladder Pain Syndrome Based on Novel Alivio Inflammation-Targeting Technology

Nov 14, 2016: Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain

Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society

Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis

Nov 19, 2012: First patient dosed with Namisol in a Phase II trial in patients with chronic post-surgical abdominal pain

Oct 15, 2012: First patient dosed with Namisol in a second phase II study in Chronic Pancreatitis

Oct 06, 2011: First Chronic Pancreatitis patient dosed with Namisol

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Visceral Pain, H2 2018  
Number of Products under Development by Companies, H2 2018  
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Universities/Institutes, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Universities/Institutes, H2 2018  
Number of Products by Stage and Target, H2 2018  
Number of Products by Stage and Target, H2 2018 (Contd.1), H2 2018  
Number of Products by Stage and Mechanism of Action, H2 2018  
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.1), H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Visceral Pain - Pipeline by Addex Therapeutics Ltd, H2 2018  
Visceral Pain - Pipeline by Anavex Life Sciences Corp, H2 2018  
Visceral Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2018  
Visceral Pain - Pipeline by Artelo Biosciences Inc, H2 2018  
Visceral Pain - Pipeline by Astellas Pharma Inc, H2 2018  
Visceral Pain - Pipeline by Cadila Healthcare Ltd, H2 2018  
Visceral Pain - Pipeline by Chromocell Corp, H2 2018  
Visceral Pain - Pipeline by Echo Pharmaceuticals BV, H2 2018  
Visceral Pain - Pipeline by Eisai Co Ltd, H2 2018  
Visceral Pain - Pipeline by Eli Lilly and Co, H2 2018  
Visceral Pain - Pipeline by Grunenthal GmbH, H2 2018  
Visceral Pain - Pipeline by Idera Pharmaceuticals Inc, H2 2018  
Visceral Pain - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018  
Visceral Pain - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018  
Visceral Pain - Pipeline by Kytogenics Pharmaceuticals Inc, H2 2018  
Visceral Pain - Pipeline by Lipella Pharmaceuticals Inc, H2 2018  
Visceral Pain - Pipeline by Pfizer Inc, H2 2018  
Visceral Pain - Pipeline by UCB SA, H2 2018  
Visceral Pain - Pipeline by Urogen Pharmaceuticals Inc, H2 2018  
Visceral Pain - Pipeline by Xigen SA, H2 2018  
Visceral Pain - Dormant Projects, H2 2018  
Visceral Pain - Dormant Projects, H2 2018 (Contd.1), H2 2018

Visceral Pain - Dormant Projects, H2 2018 (Contd.2), H2 2018

Visceral Pain - Dormant Projects, H2 2018 (Contd.3), H2 2018

Visceral Pain - Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Visceral Pain, H2 2018  
Number of Products under Development by Companies, H2 2018  
Number of Products under Development by Universities/Institutes, H2 2018  
Number of Products by Top 10 Targets, H2 2018  
Number of Products by Stage and Top 10 Targets, H2 2018  
Number of Products by Top 10 Mechanism of Actions, H2 2018  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018  
Number of Products by Routes of Administration, H2 2018  
Number of Products by Stage and Routes of Administration, H2 2018  
Number of Products by Molecule Types, H2 2018  
Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Addex Therapeutics Ltd  
Anavex Life Sciences Corp  
Arena Pharmaceuticals Inc  
Artelo Biosciences Inc  
Astellas Pharma Inc  
Cadila Healthcare Ltd  
Chromocell Corp  
Echo Pharmaceuticals BV  
Eisai Co Ltd  
Eli Lilly and Co  
Grunenthal GmbH  
Idera Pharmaceuticals Inc  
Ironwood Pharmaceuticals Inc  
Kyorin Pharmaceutical Co Ltd  
Kytogenics Pharmaceuticals Inc  
Lipella Pharmaceuticals Inc  
Pfizer Inc  
UCB SA  
Urogen Pharmaceuticals Inc  
Xigen SA

## I would like to order

Product name: Visceral Pain - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/V8DFF267E49EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V8DFF267E49EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970